Last reviewed · How we verify
Epogen Amgen
Epogen (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.
Epogen (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients on chemotherapy, Anemia in patients undergoing elective surgery.
At a glance
| Generic name | Epogen Amgen |
|---|---|
| Also known as | Epoetin Alfa |
| Sponsor | Pfizer |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Biologic |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a recombinant human erythropoietin that mimics the natural hormone responsible for regulating red blood cell production. By activating the erythropoietin receptor on erythroid progenitor cells in the bone marrow, it promotes their proliferation and differentiation into mature red blood cells. This mechanism is used to treat anemia in patients with chronic kidney disease, cancer patients on chemotherapy, and those undergoing surgery.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in cancer patients on chemotherapy
- Anemia in patients undergoing elective surgery
Common side effects
- Hypertension
- Headache
- Thrombotic events (DVT, PE, stroke)
- Pure red cell aplasia
- Injection site reactions
- Flu-like symptoms
Key clinical trials
- Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration (PHASE2)
- A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen) (PHASE1)
- Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients (PHASE3)
- A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin (PHASE3)
- A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin (PHASE3)
- A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients (NA)
- A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment (PHASE1)
- AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |